Android app on Google Play

GlobeImmune (GBIM) Files $69M IPO

July 2, 2012 5:33 PM EDT Send to a Friend
GlobeImmune, Inc. (Nasdaq: GBIM) filed a registration with the U.S. Securities and Exchange Commission for an Initial Public Offering of its Common Stock. The proposed maximum offering price is $69 million. GlobeImmune applied to list on the Nasdaq Global Market under the ticker, "GBIM."

The offering is being made through Wells Fargo Securities, Piper Jaffray, and JMP Securities.

GlobeImmune is a biopharmaceutical company focused on developing therapeutic products for cancer and infectious diseases based on our proprietary Tarmogen platform.




You May Also Be Interested In


Related Categories

IPOs

Related Entities

Piper Jaffray, JMP Securities, Wells Fargo

Add Your Comment